These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15945422)

  • 1. [Dutasteride (Avodart): a novel 5-alpha reductase inhibitor for treatment of benign prostate hypertrophy].
    Vanden Bossche M; Sternon J
    Rev Med Brux; 2005; 26(2):103-6. PubMed ID: 15945422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dutasteride: a new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Brown CT; Nuttall MC
    Int J Clin Pract; 2003 Oct; 57(8):705-9. PubMed ID: 14627182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of prostatic adenoma patients with inhibitor of 5-alpha-reductase of type I and II avodart (dutasteride)].
    Aliaev IuG; Vinarov AZ; Lokshin KL; Spivak LG
    Urologiia; 2006; (6):83-6. PubMed ID: 17315721
    [No Abstract]   [Full Text] [Related]  

  • 4. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
    Dolder CR
    Ann Pharmacother; 2006 Apr; 40(4):658-65. PubMed ID: 16569804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
    Siami P; Roehrborn CG; Barkin J; Damiao R; Wyczolkowski M; Duggan A; Major-Walker K; Morrill BB;
    Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
    Gittelman M; Ramsdell J; Young J; McNicholas T
    J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
    Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
    Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
    J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia.
    Hong SK; Min GE; Ha SB; Doo SH; Kang MY; Park HJ; Yoon CY; Jeong SJ; Byun SS; Lee SE
    BJU Int; 2010 Apr; 105(7):970-4. PubMed ID: 19793378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
    Marks LS; Roehrborn CG; Wolford E; Wilson TH
    J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.
    Roehrborn CG; Lukkarinen O; Mark S; Siami P; Ramsdell J; Zinner N
    BJU Int; 2005 Sep; 96(4):572-7. PubMed ID: 16104912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M; Fleshner NE; Finelli A; Zlotta AR
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.
    Schröder FH; Bangma CH; Wolff JM; Alcaraz A; Montorsi F; Mongiat-Artus P; Abrahamsson PA; McNicholas TA; Castro RS; Nandy IM
    BJU Int; 2009 Mar; 103(5):590-6. PubMed ID: 19226424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
    Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
    Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dutasteride (Avodart): new 5-alpha-reductase inhibitor for treating BPH.
    Gaines KK
    Urol Nurs; 2003 Jun; 23(3):218-20. PubMed ID: 12861740
    [No Abstract]   [Full Text] [Related]  

  • 20. [Dutasteride in the treatment of benign prostatic hyperplasia: an update].
    Chen HJ; Chen YR
    Zhonghua Nan Ke Xue; 2011 Jan; 17(1):63-7. PubMed ID: 21351536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.